Pre-specified secondary analysis of FINEARTS-HF (6001 patients with HFmrEF/HFpEF): finerenone's reduction in cardiovascular death and total HF events was consistent across baseline medication counts (Pinteraction=0.94), with no excess serious adverse events.
Secondary analysisn = 6,001
Hamatani et al. Finerenone, polypharmacy, and clinical outcomes in heart failure: pre-specified analysis from the FINEARTS-HF trial